Skip to main content
Clinical Trials/NCT04620278
NCT04620278
Not Yet Recruiting
N/A

Genetic Investigation of Cancer Predisposition

The University of Texas Health Science Center at San Antonio1 site in 1 country100 target enrollmentOctober 1, 2026

Overview

Phase
N/A
Intervention
Not specified
Conditions
Genetic Predisposition
Sponsor
The University of Texas Health Science Center at San Antonio
Enrollment
100
Locations
1
Primary Endpoint
Identification of somatic (tumor only) mutation
Status
Not Yet Recruiting
Last Updated
3 months ago

Overview

Brief Summary

Clinical information and samples (blood, saliva, and tumor) will be collected from patients with multiple cancers and/or a family history of cancer as well as from affected and unaffected relatives; samples will be systematically sequenced and evaluated for candidate driver mutations.

Detailed Description

Genetic screening will be performed on DNA (and/or RNA) isolated from collected samples from affected individuals by whole exome sequencing or RNA sequencing using in-house pipeline to identify candidate sequence variants. These variants will be tested for segregation with the phenotype in other relatives (affected/unaffected). Candidate variants will be subjected to additional downstream analysis, to be guided by the actual type of gene/variant.

Registry
clinicaltrials.gov
Start Date
October 1, 2026
End Date
December 1, 2035
Last Updated
3 months ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Meets at least ONE of the following:
  • Personal history (with documented diagnosis) of cancer before the age of 50
  • Personal history of more than one primary cancer
  • Documented diagnosis of cancer AND family history of that same cancer type or multiple other cancers that do not fit classical criteria of hereditary cancer syndromes
  • Documented diagnosis of a rare cancer AND family history of rare cancers that do not fit classical criteria of hereditary cancer syndromes
  • There is the same type of cancer in several generations of a family
  • Documented diagnosis of multicentric cancers (e.g bilateral cancers in paired organs, or multifocal cancers in single organs) that usually occur as single lesions when presented sporadically
  • Early onset cancer (before the age of 50, or breast cancer before age 45) AND family history of early onset cancer Capable of providing access to detailed medical records and family history of cancer

Exclusion Criteria

  • Established genetic diagnosis of a known hereditary cancer syndrome that is compatible with the clinical presentation
  • Incarcerated

Outcomes

Primary Outcomes

Identification of somatic (tumor only) mutation

Time Frame: through study completion- approximately 6-12 months

Genetic screen detects a mutation that is likely responsible for tumor development

Identification of Rare Genetic Variant in family members

Time Frame: through study completion- approximately 6-12 months

Genetic screen detects a mutation that is likely responsible for tumor development

Identification of Rare Genetic Variant

Time Frame: through study completion- approximately 6-12 months

Genetic screen detects a mutation that is likely responsible for tumor development

Secondary Outcomes

  • Identification of clinical spectrum of the disease in families(through study completion- approximately 6-12 months)

Study Sites (1)

Loading locations...

Similar Trials